J Int Assoc Physicians AIDS Care. 1999 Jan;5(1):10-30. Unique Identifier : AIDSLINE AIDS/20700020
Mascolini M
Abstract: The number of drug combinations being used to treat HIV infections may produce a public health nightmare by creating multidrug resistance. The issue of whether to use aggressive multidrug combinations early in the infectious cycle or whether to delay treatment as long as possible remains controversial and unresolved. The use of viral markers to track disease progression is discussed. Tables illustrate the relationships between CD4+ counts and opportunistic infections, disease progression, and long-term viral load reduction. The effectiveness of different drugs combinations is discussed. Results of various clinical trials are presented.
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .